- Home
- VVPR vs CUE Comparison
VVPR vs CUE Comparison
Compare VVPR & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VVPR | CUE |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 49.6M |
| IPO Year | 2016 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VVPR | CUE |
|---|---|---|
| Price | $2.53 | $0.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | ★ 384.6K | 361.2K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $61,000.00 | ★ $7,100,000.00 |
| Revenue This Year | N/A | $36.58 |
| Revenue Next Year | N/A | $32.10 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 281.25 | N/A |
| 52 Week Low | $0.62 | $0.53 |
| 52 Week High | $8.88 | $1.75 |
Technical Indicators
Market Signals| Indicator | VVPR | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 40.51 | 31.22 |
| Support Level | $2.35 | $0.55 |
| Resistance Level | $2.67 | $0.66 |
| Average True Range (ATR) | 0.22 | 0.05 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 60.81 | 7.55 |
Price Performance
Historical ComparisonAbout VVPR VivoPower International PLC
Vivopower International PLC is a sustainable energy solutions B Corporation specializing in electric solutions for customized and ruggedized fleet applications, battery and microgrids, solar, and critical power technology and services. The company's core purpose is to provide turnkey decarbonization solutions that help customers progress toward net-zero carbon status. VivoPower operates across five reportable segments: Electric Vehicles, Sustainable Energy Solutions, Solar Development, Digital Assets, and Corporate Office, with personnel and operations in Australia, the Netherlands, the United Kingdom, the United States, and the Philippines.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.